ALK and non-small cell lung carcinoma: The use of these new therapies has improved the quality of life and increased the survival of patients, as demonstrated in their respective clinical trials, with remarkable responses in NSCLC patients carrying ALK-rearrangements [9,10,11,12,13,14,15,16].